Source - Alliance News

Syncona Ltd on Thursday noted the 2023 results of one of its life science portfolio companies, which showed a widened loss and an increase in annual expenses.

Syncona is a London-based investment company, with a portfolio of companies in the life science sector.

Autolus Therapeutics PLC, a London-headquartered cell therapy developer in which Syncona holds a roughly 12% stake, posted a pretax loss of $208.4 million in 2023, 40% wider than its 2022 loss of $148.6 million.

Basic loss per share narrowed 24% to $1.20 from $1.57.

As at December 31, the company had $239.6 million in cash, down 38% from $382.4 million at the end of 2022.

Operating expenses totalled $179.7 million, up from $143.4 million, of which $130.5 million was expenses relating to research and development.

Syncona said that the increase was due to costs associated with the company’s new Nucleus manufacturing facility in Stevenage, England, as well as contractual milestone payments and a decrease in its UK reimbursable R&D tax credits.

In February, Autolus entered a strategic partnership with BioNTech SE, a Mainz, Germany-based immunotherapy company, to collaborate on their late-stage clinical programs.

The deal involves a $50 million upfront payment from BioNTech and up to $582 million in potential option exercise and milestone payments.

This gives BioNTech the right to use Autolus’ manufacturing capacity to accelerate the development and commercialisation of its BNT211 antitumor treatment. BioNTech will also support the launch of Autolus’ obe-cel cell therapy, and receive a royalty on future sales.

Shares in Autolus were down 0.6% at $5.45 in New York on Thursday.

Syncona shares were up 0.8% at 130.18 pence each in London.

Copyright 2024 Alliance News Ltd. All Rights Reserved.

Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJ Bell logo

Related Charts

Syncona Limited (SYNC)

+0.40p (+0.36%)
delayed 13:38PM